In today’s recent session, 0.42 million shares of the Adma Biologics Inc (NASDAQ:ADMA) have been traded, and its beta is 0.56. Most recently the company’s share price was $20.29, and it changed around -$0.03 or -0.13% from the last close, which brings the market valuation of the company to $4.82B. ADMA at last check was trading at a discount to its 52-week high of $23.64, offering almost -16.51% off that amount. The share price’s 52-week low was $5.89, which indicates that the recent value has risen by an impressive 70.97% since then. We note from Adma Biologics Inc’s average daily trading volume that its 10-day average is 3.91 million shares, with the 3-month average coming to 2.68 million.
Adma Biologics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended ADMA as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Adma Biologics Inc is expected to report earnings per share of 0.14 for the current quarter.
Adma Biologics Inc (NASDAQ:ADMA) trade information
Instantly ADMA has been showing red trend so far today with a performance of -0.13% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 20.70 on recent trading dayincreased the stock’s daily price by 1.98%. The company’s shares are currently up 18.33% year-to-date, but still up 8.46% over the last five days. On the other hand, Adma Biologics Inc (NASDAQ:ADMA) is 30.75% up in the 30-day period. We can see from the shorts that 14.23 million shares have been sold at a short interest cover period of 6.64 day(s).
The consensus price target as assigned by Wall Street analysts is $18, which translates to bulls needing to decrease their stock price by -12.72% from its current value. Analyst projections state that ADMA is forecast to be at a low of $18 and a high of $18.
Adma Biologics Inc (ADMA) estimates and forecasts
The year-over-year growth rate is expected to be 16.13%, up from the previous year.
Consensus estimates provided by 3 financial analysts predict the company will bring in an average of 116.4M in revenue for the current quarter. 3 analysts expect Adma Biologics Inc to make 121.3M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 81.88M and 107.19M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 42.17%. Forecasts for the next quarter put sales growth at 13.16%.
Adma Biologics Inc earnings are expected to increase by 45.61% in 2025, but the outlook is positive 30.55% per year for the next five years.
Adma Biologics Inc (NASDAQ:ADMA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.60% of Adma Biologics Inc shares, and 88.42% of them are in the hands of institutional investors. The stock currently has a share float of 90.79%. Adma Biologics Inc stock is held by 438.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 8.1462% of the shares, which is about 18.64 million shares worth $208.45 million.
VANGUARD GROUP INC, with 6.3426% or 14.52 million shares worth $162.3 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
iShares Core S&P Small-Cap ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Feb 28, 2025. The former held 15.07 shares worth $303.97 million, making up 6.34% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 7.0 shares worth around $141.26 million, which represents about 2.95% of the total shares outstanding.
